Dendritic cell vaccine - DanDrit Biotech

Drug Profile

Dendritic cell vaccine - DanDrit Biotech

Alternative Names: MCV - DanDrit Biotech; MelCancerVac

Latest Information Update: 08 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DanDrit Biotech A/S
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Colorectal cancer
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 01 Sep 2016 DanDrit Biotech has various patents pending for Dendritic cell vaccine (DanDrit Biotech 10-K, September 2016).
  • 16 Jun 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer in Denmark (SC)
  • 28 Apr 2015 DanDrit Biotech and the GISCAD Foundation plan for the phase III VIVA trial for Colorectal cancer (Adjuvant therapy, Prevention of relapse, late-stage disease, Metastatic disease) in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top